Antengene Corporation Limited (HKG:6996)

Market Cap	3.25B
Revenue (ttm)	97.85M
Net Income (ttm)	-339.74M
Shares Out	679.45M
EPS (ttm)	-0.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,427,000
Average Volume	8,406,839
Open	5.190
Previous Close	5.240
Day's Range	4.720 - 5.300
52-Week Range	0.500 - 5.920
Beta	1.06
RSI	58.99
Earnings Date	Aug 22, 2025

About Antengene Corporation

Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor f...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 169
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6996

Financial Performance

In 2024, Antengene Corporation's revenue was 91.95 million, an increase of 36.62% compared to the previous year's 67.31 million. Losses were -319.25 million, -45.07% less than in 2023.

Financial numbers in CNY